Results 161 to 170 of about 125,935 (288)

In vivo and in vitro studies of immune responses induced by normal or attenuated 'Schistosoma mansoni' schistosomula [PDF]

open access: yes
A schistosome vaccine would be of great value in controlling schistosomiasis. Exposure of experimental animals to live gamma-irradiated cercariae (GI) is highly effective and although not logistically feasible for ...
Mansour, Nuha Ramsis Nasief
core   +1 more source

Application of leukocyte filters to obtain a preparation of cytokine-induced killer cells

open access: yesMedical Immunology (Russia)
The ability of cytokine-induced killer (CIK) cells to recognize and lyse tumor cells has been shown in preclinical in vitro studies. The database ClinicalTrials.gov currently registers over 600 completed clinical studies on cellular immunotherapy including more than 30 trials with CIK cells ...
Yu. V. Gelm   +6 more
openaire   +2 more sources

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang   +10 more
wiley   +1 more source

Genetic Code Expanded T Cell for Controllable Immunotherapy

open access: yesAdvanced Science, EarlyView.
Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang   +4 more
wiley   +1 more source

CD44‐Targeting Hydroxyapatite Nanoparticles (HAP) Induce Mitochondrial Dysfunction‐Driven PANoptosis and Immunogenic Cell Death (ICD) via Ca Overload in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
ABSTRACT Colorectal cancer (CRC) remains therapeutically challenging due to high metastasis, recurrence, and immunotherapy resistance driven by tumor microenvironment‐mediated immune evasion. Immunogenic cell death (ICD) offers a promising strategy to reshape the immune microenvironment, yet existing ICD inducers suffer from poor targeting efficiency ...
Yao Xiao   +12 more
wiley   +1 more source

Cytokine-induced memory-like natural killer cells in systemic lupus erythematosus patients

open access: yesAdvances in Rheumatology
Background Natural killer (NK) cell abnormalities may contribute to the pathogenesis of systemic lupus erythematosus (SLE). Interleukin (IL)-15, an immunoregulatory cytokine crucial for NK survival, is overexpressed in SLE patients.
Chien-Ya Hsu   +5 more
doaj   +1 more source

Dual‐Stage Microneedle Patch With Lipid Droplet‐Mediated ‘Capture‐Kill’ and Sustained Release for Enhanced Wound Healing

open access: yesAdvanced Science, EarlyView.
We report a lipid‐droplet‐engineered, gallium‐loaded sonodynamic therapeutic platform (LDTG) incorporated into a bilayer microneedle (MN) patch co‐delivering all‐trans retinoic acid (ATRA), termed LDTG A‐MNs, for synergistic antibacterial therapy and accelerated wound repair.
Peng Jiang   +9 more
wiley   +1 more source

Amplification of Endoplasmic Reticulum Stress via Inhibiting Lipid Droplet Formation to Enhance Chemodynamic Immunotherapy

open access: yesAdvanced Science, EarlyView.
An endoplasmic reticulum (ER)‐targeted chemodynamic nanoagent (TCBQ/iLD‐ER NPs) comprising •OH‐generating tetrachloro‐1,4‐benzoquinone (TCBQ) and lipid droplets (LDs) formation inhibitor (iLD) is developed for chemodynamic immunotherapy of tumors. After ingestion by cancer cells, TCBQ/iLD‐ER NPs preferentially accumulate in the ER and react with ER ...
Huilan Cai   +12 more
wiley   +1 more source

An Exploratory in vitro Study of Cytotoxicity and Cytokine Profiling of Cytokine-Induced Killer (CIK) Cells Against HCT-15 Colorectal Cancer (CRC) Cells

open access: yesImmunoTargets and Therapy
Sze-Piaw Chin,1,2 Natasha Najwa Nor Arfuzir,1 Vivian Wai-Ping Kong,3 Soon-Keng Cheong1,2 1Department of Research and Development, Cytopeutics Sdn Bhd, Cyberjaya, Selangor, Malaysia; 2M.
Chin SP   +3 more
doaj  

Home - About - Disclaimer - Privacy